Radiotherapy + Sintilimab + Bevacizumab Biosimilar for uHCC With PVTT

Summary

This study was a prospective, single-arm, single-center, phase II exploratory clinical study. To investigate the efficacy and safety of radiotherapy combined with sintilimab and bevacizumab biosimilar in the treatment of unresectable hepatocellular carcinoma with portal vein tumor thrombus.

Timeline

Start

2022-08-01

Primary completion

2024-10-01

Completion

2024-10-01

Drugs

Indications